The blood-brain-barrier (BBB) represents a near-impenetrable hurdle against the delivery of therapeutic to the central nervous system. Since only small compounds can cross the BBB, this reduces the treatments available for neurodegenerative diseases and cancer1. Polymer nanoparticles (NPs) have emerged as a potential solution for delivering therapeutics across the BBB to brain targets. The development of in vitro methods for quantifying NP transport behavior represents an invaluable tool for assessing therapeutic delivery capabilities2. In this work, we modelled NP transport across a previously established 3D in vitro microfluidic model of the human BBB, where a self-assembled microvasculature from human induced-pluripotent stem cell-derived endothelial cells, brain pericytes and astrocytes are supported within an extracellular matrix and fibrin gel3. Differences in NP transport were observed between commercially available polystyrene and in-house produced polyurethane NPs. The platform was also capable of elucidating the effect of surface-grafted human holo-transferrin, an attractive brain-associated ligand, on NP transport across the BBB. Importantly, a pre-clinical model and protocol are presented for reliably testing the transport capabilities of nanocarriers, with the aim to optimize their design for therapeutic delivery across the human BBB.

Model of Nanoparticles Transport across the human Blood-Brain-Barrier Microvasculature / WL Lee, Sharon; Campisi, Marco; Osaki, Tatsuya; Possenti, Luca; Adriani, Giulia; Mattu, Clara; Kamm, Roger D.; Chiono, Valeria. - (2019). (Intervento presentato al convegno Delivering Therapeutics Across Biological Barriers tenutosi a Dublin, Ireland nel May 6-9, 2019).

Model of Nanoparticles Transport across the human Blood-Brain-Barrier Microvasculature

Marco Campisi;Clara Mattu;Valeria Chiono
2019

Abstract

The blood-brain-barrier (BBB) represents a near-impenetrable hurdle against the delivery of therapeutic to the central nervous system. Since only small compounds can cross the BBB, this reduces the treatments available for neurodegenerative diseases and cancer1. Polymer nanoparticles (NPs) have emerged as a potential solution for delivering therapeutics across the BBB to brain targets. The development of in vitro methods for quantifying NP transport behavior represents an invaluable tool for assessing therapeutic delivery capabilities2. In this work, we modelled NP transport across a previously established 3D in vitro microfluidic model of the human BBB, where a self-assembled microvasculature from human induced-pluripotent stem cell-derived endothelial cells, brain pericytes and astrocytes are supported within an extracellular matrix and fibrin gel3. Differences in NP transport were observed between commercially available polystyrene and in-house produced polyurethane NPs. The platform was also capable of elucidating the effect of surface-grafted human holo-transferrin, an attractive brain-associated ligand, on NP transport across the BBB. Importantly, a pre-clinical model and protocol are presented for reliably testing the transport capabilities of nanocarriers, with the aim to optimize their design for therapeutic delivery across the human BBB.
File in questo prodotto:
File Dimensione Formato  
ABSTRACT_Conference_Keystone_Symposia_05feb2019.pdf

accesso aperto

Descrizione: Abstract principale
Tipologia: Abstract
Licenza: PUBBLICO - Tutti i diritti riservati
Dimensione 35.25 kB
Formato Adobe PDF
35.25 kB Adobe PDF Visualizza/Apri
Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics.pdf

accesso aperto

Descrizione: Conference Program
Tipologia: Altro materiale allegato
Licenza: PUBBLICO - Tutti i diritti riservati
Dimensione 197.38 kB
Formato Adobe PDF
197.38 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11583/2852745